Overview

• The EMA concluded after a comprehensive review that semaglutide-containing drugs double the risk of non-arteritic anterior ischemic optic neuropathy in adults with type 2 diabetes.
• The neuropathy is classified as a very rare side effect, affecting about one in 10,000 users per year.
• The review drew on preclinical data, clinical trials, post-marketing adverse-reaction reports and scientific literature.
• Manufacturers of Ozempic, Wegovy and Rybelsus must update labeling to include NAION as a very rare adverse effect.
• Patients who experience sudden vision loss or rapid deterioration of vision must seek immediate medical attention.